Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact Looking to 2017 European Society of Cardiology Congress, Barcelona, Spain FOURIER, REVEAL and CANTOS in context Positive topline results from the REVEAL trial with anacetrapib, a cholesteryl ester transfer protein inhibitor, and the CANTOS trial with canakinumab, an interleukin-1β inhibitor, have fuelled expert debate about the future management of residual vascular risk. New PCSK9 Forum Associate Editor, Professor Anthony Wierzbicki discusses what these findings could mean for the management of high risk patients. Read the report and watch the video » Visit the Forum at www.pcsk9forum.org for the full results to be presented in Barcelona this summer. Check back for the latest news and views about PCSK9 science and translation to the clinic Like us on Facebook For the latest updates, PCSK9 news and analysis. Follow us on Twitter Hot topics, news and conference reports. YouTube Channel For videos, interviews and webcasts from leading experts. Our popular therapeutic guide Read online & download second edition now » Register now at www.pcsk9forum.org to receive the updated third edition e-book with post ACC17 content including the FOURIER trial. Questions & Answers Read the full answer and other questions on the PCSK9 Forum » Educational Partners and Supporters Copyright PCSK9 Forum 2017. Please click here to unsubscribe from future mailings.